Today: 14 May 2026
Linde stock edges higher in thin year-end trade as investors eye Fed minutes
30 December 2025
2 mins read

Linde stock edges higher in thin year-end trade as investors eye Fed minutes

NEW YORK, December 30, 2025, 12:34 ET — Regular session

  • Linde shares rose about 0.2% in midday trading, outperforming a slightly softer broader market.
  • Trading has been subdued in the final week of the year as investors position around the New Year’s holiday.
  • Focus is shifting to the Federal Reserve’s next signals on rate cuts and Linde’s early-February earnings window.

Linde plc shares edged higher on Tuesday as investors navigated thin year-end trading and awaited fresh signals on U.S. interest rates. The industrial gases company’s stock was up 0.2% at $427.21 by midday, while the SPDR S&P 500 ETF was down 0.1%.

The small move matters now because late-December trading can exaggerate price swings. Investors are also watching for central bank clues that could move bond yields and, by extension, valuations across industrial and materials-linked names.

“I wouldn’t try to make too much out of anything that happens in a holiday-shortened week and very light trading volume,” said Art Hogan, chief market strategist at B Riley Wealth. Reuters

Linde traded between $423.31 and $427.64 on the day after opening at $424.00, after an early dip that briefly put the stock near its session low.

Peer Air Products & Chemicals was up 0.2% in midday trade, keeping the industrial gases space largely steady as investors weighed macro headlines.

Across Wall Street, heavyweight technology shares have been under renewed pressure into the final week of the year, and trading volumes have been light in the holiday-truncated stretch, with U.S. markets closed Thursday for New Year’s Day.

Linde is widely viewed as a read-through on industrial activity because it supplies oxygen, nitrogen and hydrogen to factories and hospitals under long-running customer relationships. The company last updated investors on October 31, when it beat third-quarter earnings expectations but forecast fourth-quarter adjusted earnings per share of $4.10 to $4.20, citing weaker volumes in its Europe, Middle East and Africa business.

In that third-quarter update, Linde also projected full-year 2025 adjusted diluted earnings per share of $16.35 to $16.45.

Rate expectations are part of the backdrop for industrial bellwethers like Linde. Investors are looking for more detail in minutes from the Federal Reserve’s Dec. 9–10 meeting, after the central bank reduced rates by a quarter of a percentage point and markets turned to how quickly borrowing costs might fall in 2026.

A basis point is one-hundredth of a percentage point. Moves in rate expectations can shift the appeal of steady cash-generating companies versus faster-growth stocks, especially during periods of market rotation.

For Linde specifically, investors will be watching for signs that European volumes stabilize, and whether pricing discipline holds up as customers manage costs in a slower industrial backdrop. New hydrogen and clean-energy projects remain a longer-term demand theme, but traders tend to focus first on near-term volumes and margin resilience.

The next big catalyst is the company’s next earnings report, which market calendars estimate around Feb. 5. Investors typically look to that update for 2026 guidance and any changes in the pace of customer demand across regions.

On the tape, Tuesday’s low near $423 marked the nearest support area, with $428 forming the top end of the day’s range. With year-end liquidity thin, traders said those levels can matter because automated orders can amplify short-term moves.

Stock Market Today

  • Nurix Therapeutics Stock: Is Its Premium 23.3x Price-to-Sales Multiple Justified?
    May 14, 2026, 9:02 AM EDT. Nurix Therapeutics (NRIX) shares rose 1.38% to $16.18 amid mixed recent performance, down 10% year to date but up nearly 69% over one year. The stock trades at a high price-to-sales (P/S) multiple of 23.3x, well above the US biotech average of 9.7x. This premium reflects strong analyst revenue growth forecasts of 42.2% annually, outpacing the broader market. However, Nurix remains loss-making with $295 million in ongoing losses and a $1.65 billion market cap, making it vulnerable to clinical setbacks. Investors should weigh the high growth potential against risks in this early-stage biotech before assuming the premium valuation is sustainable.

Latest articles

Apple Backs Google in EU AI Fight as iPhone Rules Loom

Apple Backs Google in EU AI Fight as iPhone Rules Loom

14 May 2026
Apple warned the European Commission that proposed EU rules forcing Google’s Android to open core features to rival AI assistants could endanger privacy, security, and device performance. The Commission’s feedback period closed Wednesday, with a final decision expected by July 27. Apple argued the measures could set a precedent for its own platforms. Google also opposes the plan, calling it an “unwarranted intervention.”
Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

14 May 2026
Precigen shares jumped 14.1% in early trading after first-quarter revenue reached $23.3 million, beating estimates, and net loss narrowed to $7.9 million from $54.2 million a year earlier. Papzimeos, its new RRP therapy, generated $21.6 million in net product revenue. The company ended March with $56.7 million in cash and expects current funds and Papzimeos sales to last through 2026.
POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

14 May 2026
POET Technologies signed a supply and joint-development agreement with Lumilens, including a $50 million initial order for optical engines used in AI data-center networks. The companies said cumulative purchases could exceed $500 million over five years. POET shares rose 16% after the news. First engineering samples are expected in late 2026, with production targeted for 2027.
PepsiCo (PEP) stock edges lower today as Fed minutes loom and leadership shuffle takes effect
Previous Story

PepsiCo (PEP) stock edges lower today as Fed minutes loom and leadership shuffle takes effect

Gold Fields stock rebounds as gold steadies, with Fed minutes next
Next Story

Gold Fields stock rebounds as gold steadies, with Fed minutes next

Go toTop